CGeneTech announced the completion of a Series A financing round of nearly RMB 100 million on the 12th of February

Categories:Company News
Author:BioBAY
Origin:
Time of issue:2017-12-12
Views:0

(Summary description)CGeneTech (Suzhou, China) Co., Ltd. announced at a financing conference on December 12 that it has completed a Series A financing round of nearly RMB 100 million. The round was co-led by Yipu Capital and Tongren Boda, with joint participation from QianFin Capital and Ida Capital. CGeneTech plans to use this round of financing for clinical trials of two products, including Class I innovative drugs, and to continue to expand its R&D and registration filing team, as well as to further expand its pipeline and advance subsequent new drug projects into the clinic. Zhang Dongchi, Director of Suzhou Science and Technology Bureau, attended the launch and witnessed the event.

CGeneTech announced the completion of a Series A financing round of nearly RMB 100 million on the 12th of February

(Summary description)CGeneTech (Suzhou, China) Co., Ltd. announced at a financing conference on December 12 that it has completed a Series A financing round of nearly RMB 100 million. The round was co-led by Yipu Capital and Tongren Boda, with joint participation from QianFin Capital and Ida Capital. CGeneTech plans to use this round of financing for clinical trials of two products, including Class I innovative drugs, and to continue to expand its R&D and registration filing team, as well as to further expand its pipeline and advance subsequent new drug projects into the clinic. Zhang Dongchi, Director of Suzhou Science and Technology Bureau, attended the launch and witnessed the event.

Categories:Company News
Author:BioBAY
Origin:
Time of issue:2017-12-12
Views:0

CGeneTech (Suzhou, China) Co., Ltd. announced at a financing conference on December 12 that it has completed a Series A financing round of nearly RMB 100 million. The round was co-led by Yipu Capital and Tongren Boda, with joint participation from QianFin Capital and Ida Capital. CGeneTech plans to use this round of financing for clinical trials of two products, including Class I innovative drugs, and to continue to expand its R&D and registration filing team, as well as to further expand its pipeline and advance subsequent new drug projects into the clinic. Zhang Dongchi, Director of Suzhou Science and Technology Bureau, attended the launch and witnessed the event.

Founded in 2010, Centurion Biomedical Technologies (Suzhou) Co., Ltd. is dedicated to the research, development, production and sales of small molecule innovative drugs. The company has a 1,000 sqm R&D laboratory and advanced instruments and equipment in the Biomedical Industrial Park, and has built up a comprehensive management system. In 2012, Cetagliptin, its original patented Class I hypoglycemic drug, was successfully shortlisted for the National 12th Five-Year Plan "Major New Drug Creation", and was included in the track of key support for innovative drugs at the national level, and was granted clinical approval for Class I new drugs in 2017. These drugs are safe and effective, do not cause fasting hypoglycemia, do not increase patients' weight and are orally administered, and have attracted widespread attention from the pharmaceutical industry in recent years. This financing will also focus on advancing the Phase I clinical trials of this drug. At the same time, Centurion's flash-release formulation technology has been awarded the title of Suzhou Engineering Centre, and on this platform has developed new drug projects in special formulations represented by Asenapine.

Dr. Qiang Yu, co-founder and CEO of Centec, graduated from the Chemistry Department of Peking University and completed his bachelor's thesis in the research group of Academician Qiyi Xing. He then participated in the national "863" research project at the Chinese Academy of Sciences and was the first author of a paper published in a professional journal in the United States. He then obtained his PhD in chemistry in the USA and his research was cited by Nobel Laureate Lehn, Jean-Marie in the internationally renowned journal Nature. In 2002, Dr Yu started working in the US pharmaceutical industry and in 2005, he founded his own company in the US, helping to develop and market the CaCO-2 cells as an irreplaceable model for drug bioefficacy evaluation. In 2010, Dr. Yu returned to China to build a multi-layered R&D pipeline, leveraging his extensive experience in the pharmaceutical industry to target the $100 billion pharmaceutical market. In 2013, Dr. Yu was selected as an expert for the National Major Talent Introduction Project and is the project leader for the National Major New Drug Creation Project.

Dr. Yu said, "The angel and Pre-A rounds of financing completed before 2016 have provided solid funding for the company's early stage new drug development projects, and we are focused on providing better solutions for patients in various disease areas. The completion of this new Series A financing will accelerate Centurion's product advancement and expansion of multiple product lines in cancer, brain injury, leukemia and more. The lead investors of this financing, YIP Park Capital and Tong Ren Boda, both have very deep resources in the medical field, and Qian Capital and Ida Capital are also well-known in the industry. Together with the previous investors, Zhong Xin Venture Capital and Shan Lan Capital, CGeneTech will grow rapidly and continue to hang its sails to help Haiti with the belief of Sheng De, Innovation, Only Truth, and Ze Shi, because we know that our daily work is the hope of patients' hearts. "

翼朴资本蔡志洋先生表示：“我们处在中国创新药即将蓬勃发展的大时代，真正具备创新研发能力和临床经验的企业将面临前所未有的机遇。我们高度认可余强博士及其团队在小分子创新药领域的研发经验和能力，并高度看好盛世泰科产品及研发管线未来的市场潜力。我们非常荣幸能够参与到这样一项伟大的事业之中，并衷心祝愿公司继续脚踏实地，奋勇争先，早日为国内患者带来福音。”

共同领投方同人博达是专注于医药和器械领域的专业化股权投资机构，一直关注盛世泰科的成长。同人博达非常认可公司核心团队的专业能力和职业素养，对公司降糖新药盛格列汀在临床前的优异表现，特别是潜在的降血脂等心血管获益趋势方面给予了高度评价。同人博达希望通过支持盛世泰科的新药研发项目，推动其打造和完善自身新药创制与创新制剂技术平台，成为具有国际研发能力和产业竞争力的国内一流医药企业。

Previous: Perfect conclusion of the 12th Five-Year Plan major new drug creation project

Next: CGeneTech's Class I innovative drug Centagliptin phosphate enters Phase I clinic

Previous: Perfect conclusion of the 12th Five-Year Plan major new drug creation project

Next: CGeneTech's Class I innovative drug Centagliptin phosphate enters Phase I clinic

Shengshi Taike: Exchange 'One Promise, One Thousand Gold' for 'Dreams Come True'

Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future". On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang. Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。 Funds - the 'first pot of gold' that leverages innovation leverage In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes. "China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies. Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile. Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution fr

2025-01-07

Milestones | Shengshi Taike's new generation DPP-4 inhibitor approved for market launch

Today, the official website of the National Medical Products Administration (NMPA) of China announced that Shengshi Taike's independently developed Class 1 innovative drug, saxagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China. This is a new generation of highly selective DPP-4 inhibitor, which is suitable for improving the blood sugar control of adult type 2 diabetes patients. According to the Guidelines for the Prevention and Treatment of Type 2 diabetes in China, the prevalence of diabetes among adults in China has risen to 11.2%, of which more than 90% are type 2 diabetes. In order to meet the huge clinical demand, some new drugs with different mechanisms of action from traditional oral hypoglycemic drugs have emerged in recent years. Dipeptidyl peptidase-4 (DPP-4) inhibitors are one of them. They not only improve hyperglycemia, but also are not easy to induce hypoglycemia and weight gain. They have the characteristics of rapid oral absorption, long half-life, and long-lasting effect, and are known as "smart" hypoglycemic drugs. Currently, they have been recommended by many domestic and foreign guidelines. As a new generation of highly selective DPP-4 inhibitor independently developed by Shengshi Taike, sengliptin has been continuously selected for the national "Major New Drug Development" special projects in the 12th and 13th Five Year Plans. Due to the excellent data demonstrated in the first phase clinical trial of the best product in the market, it was exempted from phase 2 clinical trials and directly entered phase 3 clinical trials, pioneering the "exemption from two to three" clinical trials in the field of this drug. The results of the phase III clinical trial of Sengliptin led by Professor Ji Linong, director of the Endocrinology Department of Peking University People's Hospital and director of Peking University diabetes Center, showed that in the single drug treatment trial of Sengliptin, the reduction values of HbA1c in the 50mg and 100mg dose groups at the end of the 24th week were 1.08% and 1.07% respectively; In the treatment trial of sengliptin combined with metformin, the glycated hemoglobin decreased by 1.23% and 1.17% in the 50mg and 100mg dose groups at the end of the 24th week, respectively. Meanwhile, both sets of experimental data showed that patients with higher blood sugar levels experienced a greater decrease in glycated hemoglobin levels. In addition to its excellent hypoglycemic effect, what is even more commendable is that in the comparison between the 100mg dose group (high-dose group) and the placebo group in the last 28 weeks, the incidence of adverse reactions of sengliptin is similar to that of the placebo group, and its safety further solves the common adverse reactions in marketed products. At present, metformin combined with leptin has become the main treatment scheme in the clinical application of treating type 2 diabetes. According to Sullivan's research report, by 2030, the market size of leptin in China will exceed 30 billion, with broad market prospects. Ding Juping, the co-founder and president of Shengshi Tyco, said: "I am very glad to see the company's self-developed product, Sengliptin Phosphate Tablets, has been approved for listing. This drug will be the best new hypoglycemic drug of its kind with half the effort and twice the treatment effect. I hope it will benefit the majority of diabetes patients in China as soon as possible after it is approved for listing." Dr. Yu Qiang, the founder and CEO of Shengshi Tyco, said: "Sengliptin's successful approval for listing benefits from Suzhou and the park as a fertile land for entrepreneurship and the strong support of many departments. It is also a" promise of gold "to use our innovative drugs to repay the business friendly services in Suzhou Park. At this moment, I would like to use an original poem to bless this new drug for its successful launch." Morimu's sounds of nature are listed in the palace. The morning light shines on the clouds, and the prosperous world welcomes the sunrise.

2024-12-05